Abstract
Clinical laboratory tests are commonly used for supporting the diagnosis and prognosis of a disease, monitoring the efficacy progress of therapeutic management decisions, and measuring the foreign toxins. Recent advances in genomics have resulted in the generation of new assay panels to support personalized drug therapy – this offers new opportunities for clinical laboratories to make important contributions to healthcare. Pharmacogenomics (PGx) is a recognized discipline within pharmacology that involves testing relevant human genes, whose products are involved with the inter-individual variability of a drug’s pharmacokinetics, pharmacodynamics, and human leukocyte antigen (HLA) system profile. The effective use of PGx testing promises to improve the therapeutic efficacy of drugs while reducing the incidence and severity of adverse drug effects, and drive the optimum drug selection for therapy.
Parts of this chapter was published in Wu et al. [12] with permission from Future Medicine Ltd., http://www.futuremedicine.com/loi/pgs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Spear, B. B., Heath-Chiozzi, M., & Huff, J. (2001). Clinical application of pharmacogenetics. Trends in Molecular Medicine, 7, 201–204.
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. The Journal of the American Medical Association, 279, 1200–1205.
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley T. J., et al. (2004). Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. British Medical Journal, 329, 15–19.
Aspden, P., Wolcott, J., Bootman, J. L., & Cronenwett, R. L., (Eds.). (2007). Preventing medication errors: Committee on identifying and preventing medication errors. Washington: National Academic Press.
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomazic, J., et al. (2008). HLA-B*5701 screening for hypersensitivity to abacavir. The New England Journal of Medicine, 358, 568–579.
Chung, W. H., Hung S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., et al. (2004). Medical genetics: A marker for Stevens-Johnson syndrome. Nature, 428, 486–486.
Kalow, W. (1990). The pennsylvania state university college of medicine 1990 Bernard B. Brodie lecture: Pharmacogenetics: Past and future. Life Sciences, 47, 1385–1397.
Evans, D., Manley, K., & McKusick, V. (1960). Genetic control of isoniazid metabolism in man. British Medical Journal, 2, 485–491.
Weinshilboum, R. M., & Wang, L. (2006). Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annual Review of Genomics and Human Genetics, 7, 223–245.
Collins, F. S., Morgan, M., & Patrinos, A. (2003). The human genome project: Lessons from large-scale biology. Science, 300, 286–290.
Vogel, F., & Jager, P. (1969). The genetic load of a human population due to cystostatic agents. Humangenetik, 7, 287–304.
Wu, A. H. B., Babic, N., & Yeo, K. T. J. (2009). Implementation of pharmacogenomics into the clinical practice of therapeutics: Issues for the clinician and the laboratorian. Personalized Medicine, 6, 315–327.
Jensen, T. S., Jacques, L. B., Ciccanti, M., Long, K., Eggleston, L., & Roche, J. (2010). Proposed decision memo for pharmacogenomic testing to predict warfarin responsiveness. Accessed May 17, 2010, from http://www.cms.gov/mcd/viewdraftdecisionmemo.asp?from2=viewdraftdecisionmemo.asp&id=224&
Wong, S. H., Happy, C., Blinka, D., Gock, S., Jentzen, J. M., Donald, Hon. J., et al. (2010). From personalized medicine to personalized justice: The promises of translational pharmacogenomics in the justice system. Pharmacogenomics, 11(6), 731–737.
Rosenberg, Y., & Schron, E. (2010). Clarification of optimal anticoagulation through genetics (COAG); A randomized, multicenter, double-blind clinical trial to evaluate efficacy in the use of clinical plus genetic information to guide warfarin therapy initiation and improve anticoagulation control for patients. Accessed May 15, 2010, from http://coagstudy.org
Meltzer, D. O., & Marlow E. (2010). Clinical and economic implications of genetic testing for warfarin management. Accessed May 15, 2010, from http://www.clinicaltrialssearch.org/clinical-and-economic-implications-of-genetic-testing-for-warfarin-management-nct00964353.html
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Meneveau, N., et al. (2009). Genetic determinants of response to clopidogrel and cardiovascular events. The New England Journal of Medicine, 360, 363–375.
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., et al. (2009). Cytochrome P-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine, 360, 354–362.
U.S. Food and Drug Administration (2010). Reduced effectiveness of plavix (clopidogrel) in patients who are poor metabolizers of the drug. Accessed May 15, 2010, from http://www.fda.gov/drugs/drugsafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm
Epstein, R. S., Moyer, T. P., Aubert, R. E., O’Kane, D. J., Xia, F., Verbrugge, R.R., et al. (2010). Warfarin genotyping reduces hospitalization rates. Journal of the American College of Cardiology, 55, 2804–2812http://newsblog.mayoclinic.org/2010/03/16/warfarin-genetic-test-cuts-hospital-admissions/
The International Warfarin Pharmacogenetics C. (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. The New England Journal of Medicine, 360, 753–764.
Babic, N., Haverfield, E. V., Burrus, J. A., Lozada, A., Das, S., & Yeo, K. T. J. (2009). Comparison of performance of three commercial platforms for warfarin sensitivity genotyping. Clinica Chimica Acta, 406, 143–147.
Valdes, R., Payne, D., & Linder, M. (2010). Laboratory Medicine Practice Guidelines. Laboratory analysis and application of pharmacogenetics to clinical practice. Accessed November 26, from http://www.aacc.org/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/LAACP/Pages/default.aspx
Centers for Disease Control and Prevention (2010). Genetic testing reference materials coordination program (GeT-RM). Accessed November 26, http://wwwn.cdc.gov/dls/genetics/rmmaterials/MaterialsAvailability.aspx
Personalized Medicine Coalition. Accessed May 15, 2010, from http://www.personalizedmedicinecoalition.org/
Roden, D. M., Altman, R. B., Benowitz, N. L., Giacomini, K. M., Johnson, J. A., Krauss, R. M., et al. (2006). Pharmacogenomics: Challenges and opportunities. Annals of Internal Medicine, 145, 749–757.
Wilkinson, G. R. (2005). Drug metabolism and variability among patients in drug response. The New England Journal of Medicine, 352, 2211–2221.
Bolonna, A. A., Arranz, M. J., Mancama, D., & Kerwin, R. W. (2004). Pharmacogenomics – can genetics help in the care of psychiatric patients? International Review of Psychology, 16, 311–319.
Yong, W. P., & Innocenti, F. (2007). Translation of pharmacogenetic knowledge into cancer therapeutics. Clinical Advances in Hematology & Oncology, 5, 698–706.
Carlquist, J. F. (2007). Cardiovascular therapy and pharmacogenetics in 2007. Pharmacogenomics, 8, 21–23.
Giacomini, K. M., Brett, C. M., Altman, R. B., Benowitz, N. L., Dolan, M. E., Flockhart, D. A., et al. (2007). The Pharmacogenetics Research Network: From SNP discovery to clinical drug response. Clinical Pharmacology and Therapeutics, i 81, 328–345.
Pharmacogenomics knowledge base. Accessed May 17, 2010, from http://www.pharmgkb.org/
Altman, R., Schwartz, D., Berlin, D., Mittal, A., Person, M., Oppezzo, M., et al. (2010). DNA twist – A web-based tool of pharmacogenomics. Accessed May 17, 2010, from http://www.dnatwist.org/BDE/index.html
Berlin, D. S., Person, M. G., Mittal, A., Oppezzo, M. A., Chin, D. B., Starr, B., et al. (2010). DNATwist: a Web-based tool for teaching middle and high school students about pharmacogenomics. Clinical Pharmacology and Therapeutics, 87, 393–395.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Yeo, KT.J., Babic, N., Wu, A.H.B. (2011). Issues in Translation of Pharmacogenomics into Clinical Practice. In: Wu, A., Yeo, KT. (eds) Pharmacogenomic Testing in Current Clinical Practice. Molecular and Translational Medicine. Humana Press. https://doi.org/10.1007/978-1-60761-283-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-60761-283-4_1
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-282-7
Online ISBN: 978-1-60761-283-4
eBook Packages: MedicineMedicine (R0)